查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1854168

細胞免疫療法市場按類型、技術類型、適應症和設施類別分類 - 全球預測 2025-2032

Cellular Immunotherapy Market by Type, Technology Type, Indication, Institution Category - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，細胞免疫療法市場規模將達到 301.8 億美元，複合年成長率為 12.34%。

關鍵市場統計數據
基準年2024年 118.9億美元
預計年份：2025年 132.9億美元
預測年份 2032 301.8億美元
複合年成長率 (%) 12.34%

本書重點介紹塑造現代細胞免疫療法的科學創新、臨床需求和操作複雜性之間的整合。

細胞免疫療法已進入科學、臨床和商業策略整合的階段，這為價值鏈上的相關人員帶來了獨特的機會和營運挑戰。工程化細胞平台的最新進展，以及生產和監管途徑的不斷改進，正在擴大可能的治療方法範圍。同時，人們對安全性、療效持久性和成本效益的日益成長的期望，正在改變研發人員、臨床中心和合約合作夥伴對投資和規模化生產的優先排序。

因此，決策者必須權衡臨床前景與物流的現實。轉化醫學的進步正在加速候選化合物從早期發現到關鍵性試驗的進程，但這一進程需要強大的供應鏈、品管系統和戰略夥伴關係關係，以確保結果的可重複性。同樣重要的是，支付方和醫療服務提供者正在仔細審查循證策略和實際應用效果，以支持報銷和醫療服務可近性。在此背景下，本書以清晰觀點的導論開篇，揭示了技術演進與實際應用之間的相互關係，為深入分析後續的市場變化、政策阻力和組織需求奠定了基礎。

分析技術多元化、營運規模和夥伴關係模式如何重塑細胞治療領域的轉化路徑和商業性準備。

在技​​術突破和相關人員不斷變化的期望的雙重推動下，變革性轉變正在重塑細胞免疫療法的多個方面。治療方法正從第一代過繼性細胞療法發展到更複雜的工程方法、改進的安全開關以及將細胞藥物與標靶生技藥品結合的混合平台。這種多樣化促使申辦方重新評估研發路徑，以平衡差異化療效的潛力與日益複雜的生產製造和法律規範。

同時，製造業正從客製化的集中式生產轉向更標準化、模組化和可擴展的流程。自動化、封閉式系統工作流程和品質源自於設計 (QbD) 方法的進步，在提高產量的同時，也力求降低批次差異。這些營運方面的改進，與日益重視分散式臨床網路以及生物技術公司、臨床機構和專業合約組織之間的策略聯盟相輔相成。因此，夥伴關係正從交易型供應商關係演變為以共同開發、風險共用和產能協調為重點的整合式合作。總而言之，這些轉變正在加速臨床試驗的進程，同時也提升了嚴格的流程控制和相關人員之間策略合作的重要性。

對關稅上調動態將如何影響細胞治療價值鏈的供應鏈生產連續性和專案進度進行策略性評估

新關稅和貿易措施的實施給細胞免疫療法計畫帶來了巨大的營運壓力，尤其是在關鍵投入品跨境供應或專用設備供應商有限的情況下。關稅導致的試劑、一次性耗材和精密儀器的成本上漲，會立即造成採購壓力，迫使企業重新評估籌資策略和庫存政策。實際上，這通常意味著更長的前置作業時間、更高的營運成本需求，以及檢驗替代供應商以避免臨床和生產活動中斷的必要性。

除了直接的成本影響外，關稅還可能透過降低全球零件流動的彈性，並鼓勵近岸外包和區域回流，從而加劇供應鏈的脆弱性。先前依賴國際供應商網路的公司可能面臨供應商合約重新談判和設備部署延遲，這可能會影響試驗註冊時間表和生產規模擴大計畫。為了降低這些風險，許多公司正在評估本地供應商發展、多元化採購策略和策略性庫存緩衝，同時加強與監管機構的對話，探討替代材料的可接受等效性和合格途徑。

重要的是，關稅壓力的累積影響往往在整個價值鏈中分佈不均。規模較小的生物技術研發公司和採購受限的學術中心可能承受不成比例的營運負擔，而擁有多元化供應鏈和內部生產能力的大型機構可能更能抵禦短期衝擊。然而，長期的關稅環境可能會改變投資重點，加速供應鏈關係的整合，並在監管和經濟狀況允許的情況下，獎勵國內生產能力的建設。因此，相關人員應將關稅情境規劃納入其臨床開發和商業化藍圖，以維持專案的連續性和策略靈活性。

基於細分視角的深入觀點，將治療方式與輔助技術、適應症和設施能力相匹配，從而設計出切實可行的策略。

細分分析對於明確研發策略與患者群體、生產路徑和組織能力之間的匹配至關重要。按類型分類，包括 CAR-T 細胞療法、樹突細胞療法、NK 細胞療法、T 細胞受體療法和腫瘤浸潤淋巴細胞療法，每種療法都有不同的研發週期、安全性特徵和生產需求。例如，工程化 CAR-T 構建體需要先進的病毒載體生產流程和嚴格的效力檢測，而 NK 細胞療法可能更側重於擴增方案和現成的物流。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • CAR-T細胞療法的臨床應用日益廣泛
  • 擴展照護現場自動化細胞處理平台，以簡化治療工作流程
  • 不斷完善的法規結構加速了下一代基因編輯細胞免疫療法的核准
  • 人工智慧與巨量資料分析的融合將最佳化個人化細胞療法的生產過程。
  • 將CAR-T細胞療法與查核點抑制劑結合的聯合治療正在興起，以提高難治性癌症的療效。
  • 提高細胞製造效率的技術進步
  • 基於 CRISPR 的 CAR-T 細胞設計技術的進步推動了下一代免疫療法的發展。
  • 生物技術製藥策略聯盟推動細胞療法生產快速擴張
  • 新的研究重點是固態腫瘤的免疫療法策略
  • 常規生物反應器的創新提高了下一代細胞療法的可擴展生產能力。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 細胞免疫療法市場（按類型分類）

  • CAR-T細胞療法
  • 樹突細胞療法
  • NK細胞療法
  • T細胞受體治療
  • 腫瘤浸潤淋巴細胞治療

9. 依技術類型分類的細胞免疫療法市場

  • 細胞激素和免疫調節劑
  • 單株抗體

第10章 依適應症分類的細胞免疫療法市場

  • B細胞惡性腫瘤
  • 肝癌
  • 攝護腺癌
  • 腎臟細胞癌

第11章 依機構類別分類的細胞免疫療法市場

  • 學術機構
  • 生物技術和製藥公司
  • 合約組織
  • 醫院
  • 研究機構

第12章 各地區細胞免疫療法市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 細胞免疫療法市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國細胞免疫療法市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Adaptimmune Therapeutics PLC
    • Adicet Bio, Inc.
    • Apac Biotech Private Limited
    • AstraZeneca PLC
    • Atara Biotherapeutics, Inc.
    • Bellicum Phamaceuticals, Inc.
    • Bio-Rad Laboratories, Inc.
    • Bristol-Myers Squibb Company
    • Celyad Oncology SA
    • Corning Incorporated
    • Dendreon Pharmaceuticals LLC
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • Gilead Sciences, Inc.
    • GlaxoSmithKline PLC
    • Glycostem Therapeutics BV
    • Immatics NV
    • Inovio Pharmaceuticals, Inc.
    • Iovance Biotherapeutics, Inc.
    • Johnson & Johnson Services, Inc.
    • JW Therapeutics（Shanghai）Co., Ltd.
    • Lonza Group Ltd.
    • Merck KGaA
    • Novartis AG
    • Pfizer Inc.
Product Code: MRR-7C50F2739738

The Cellular Immunotherapy Market is projected to grow by USD 30.18 billion at a CAGR of 12.34% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 11.89 billion
Estimated Year [2025] USD 13.29 billion
Forecast Year [2032] USD 30.18 billion
CAGR (%) 12.34%

A focused introduction that frames the convergence of scientific innovation clinical demands and operational complexities shaping modern cellular immunotherapy

The cellular immunotherapy landscape has entered a phase where science, clinical practice, and commercial strategy converge to create distinct opportunities and operational challenges for stakeholders across the value chain. Recent advances in engineered cell platforms, coupled with iterative improvements in manufacturing and regulatory pathways, have expanded the scope of adoptable therapeutic approaches. At the same time, rising expectations around safety, durability of response, and cost-effectiveness are reshaping how developers, clinical centers, and contract partners prioritize investment and scale-up.

As a result, decision-makers must reconcile clinical promise with logistical realities. Translational progress has accelerated candidate pipelines from early discovery into pivotal studies, but this trajectory demands robust supply chains, quality management systems, and strategic partnerships to ensure reproducible outcomes. Equally important, payers and providers are scrutinizing evidence generation strategies and real-world performance to support reimbursement and access. In this context, a clear-eyed introduction clarifies the interplay between technological evolution and practical implementation, setting the stage for deeper analysis of market shifts, policy headwinds, and organizational imperatives that follow.

An analysis of how technological diversification operational scale and partnership models are reshaping translational pathways and commercial readiness in cell therapy

Transformative shifts are redefining cellular immunotherapy across multiple dimensions, and these changes are driven by both technological breakthroughs and evolving stakeholder expectations. Therapeutic modalities are diversifying beyond first-generation adoptive cell therapies to include more refined engineering approaches, improved safety switches, and hybrid platforms that combine cellular agents with targeted biologics. This diversification is prompting re-evaluation of development paths, as sponsors balance the potential for differentiated efficacy against increased complexity in manufacturing and regulatory oversight.

Concurrently, manufacturing is transitioning from bespoke, center-based production toward more standardized, modular, and scalable processes. Advances in automation, closed-system workflows, and quality-by-design approaches are enabling higher throughput while aiming to reduce batch variability. These operational improvements are complemented by a growing emphasis on decentralized clinical networks and strategic alliances between biotechnology companies, clinical institutions, and specialized contract organizations. Accordingly, partnerships are evolving from transactional vendor relationships into integrated collaborations focused on co-development, shared risk, and capacity alignment. Taken together, these shifts are accelerating clinical translation while simultaneously elevating the importance of rigorous process control and strategic alignment among stakeholders.

A strategic assessment of how elevated tariff dynamics influence supply chains manufacturing continuity and program timelines across the cell therapy value chain

The introduction of new tariffs and trade measures presents a material operational stressor for cellular immunotherapy programs, particularly where key inputs cross borders or where specialized equipment originates from a narrow set of suppliers. Tariff-driven cost increases on reagents, single-use consumables, and precision instruments can create immediate procurement pressure, prompting organizations to reassess sourcing strategies and inventory policies. In practice, this often translates into longer lead times, elevated working capital requirements, and the need to validate alternative suppliers to maintain uninterrupted clinical and manufacturing activities.

Beyond direct cost impacts, tariffs can amplify supply chain fragility by reducing the resilience of global component flows and incentivizing nearshoring or regional reshoring initiatives. Companies that previously relied on international vendor networks may encounter renegotiation of supplier contracts or delays in equipment deployment, which in turn can affect study enrollment timelines and manufacturing scale-up plans. To mitigate these risks, many organizations are evaluating localized supplier development, multi-sourcing strategies, and strategic inventory buffers, while also escalating dialogue with regulatory bodies about acceptable equivalence and qualification pathways for alternate materials.

Importantly, the cumulative effect of tariff pressures is often felt unevenly across the value chain. Smaller biotech developers and academic centers with constrained procurement leverage may experience disproportionate operational strain, whereas larger organizations with diversified supply bases and in-house manufacturing capabilities might better absorb short-term shocks. However, prolonged tariff environments have the potential to redirect investment priorities, accelerate consolidation of supply relationships, and incentivize the development of domestic manufacturing capacity where regulatory and economic conditions permit. Stakeholders should therefore integrate tariff scenario planning into clinical development and commercialization roadmaps to maintain program continuity and strategic flexibility.

Insightful segmentation-driven perspectives that align therapy modalities adjunct technologies indications and institutional capabilities for actionable strategy design

Segmentation analysis offers critical clarity when aligning development strategies to patient populations, manufacturing pathways, and institutional capabilities. Based on Type, the landscape encompasses CAR T-Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, T-Cell Receptor Therapy, and Tumor-Infiltrating Lymphocytes Therapy, each presenting distinct development timelines, safety profiles, and manufacturing needs. For example, engineered CAR T constructs demand sophisticated viral vector production and stringent potency assays, whereas NK cell approaches may emphasize expansion protocols and off-the-shelf logistics.

Based on Technology Type, the field differentiates between Cytokines & Immunomodulators and Monoclonal Antibodies, which interact with cellular therapies in combinatorial regimens and supportive care strategies. These adjunct technologies shape clinical trial design, biomarker strategies, and dosing paradigms, influencing both efficacy benchmarks and regulatory expectations. Based on Indication, the therapeutic focus spans B-Cell Malignancies, Liver Cancer, Prostate Cancer, and Renal Cell Carcinoma, each indication requiring tailored clinical endpoints, patient selection criteria, and evidence-generation approaches to demonstrate meaningful benefit.

Based on Institution Category, the ecosystem includes Academic Institutes, Biotech & Pharmaceutical Companies, Contract Organizations, Hospitals, and Research Institutes, with each actor contributing unique capabilities. Academic institutes often lead early translational research and investigator-initiated trials; biotech and pharmaceutical companies drive clinical development and commercialization strategy; contract organizations deliver scale-up and manufacturing services; hospitals provide clinical trial sites and real-world data capture; and research institutes contribute foundational science and biomarker discovery. Recognizing how these segments intersect helps stakeholders prioritize investments, select partners, and design clinical programs that reflect therapeutic modality, technological adjuncts, target indications, and institutional strengths.

Comparative regional perspectives on regulatory readiness commercial access and infrastructure scale that determine adoption pathways across global markets

Regional dynamics fundamentally affect development strategies, regulatory pathways, and commercial access for cellular immunotherapies. In the Americas, infrastructure depth, payer engagement models, and clinical trial networks support rapid patient accrual and iterative evidence generation, while commercialization requires close coordination with reimbursement stakeholders to demonstrate value and long-term outcomes. Regulatory frameworks in this region increasingly accommodate advanced therapies through expedited pathways, yet manufacturers must still navigate complex manufacturing compliance and post-approval evidence commitments.

Across Europe, Middle East & Africa, regulatory plurality and diverse healthcare financing structures create both opportunities and challenges. Certain European jurisdictions offer innovative reimbursement mechanisms for high-cost therapies, but broader market access often requires adaptive evidence strategies and region-specific health economic modeling. In some Middle Eastern and African markets, the emphasis rests on capacity building, infrastructure development, and clinician training to support safe and effective administration of cellular therapies.

The Asia-Pacific region is characterized by heterogeneity in regulatory maturity, manufacturing capacity, and clinical adoption rates. Some markets in the region are rapidly expanding local production capabilities and investing in clinical trial infrastructure, while others focus on strategic collaborations with global sponsors to access novel therapies. Across all regions, cross-border collaborations, regulatory harmonization efforts, and investments in workforce and facility readiness will be decisive factors shaping the pace at which these therapies move from clinical proof-of-concept to routine clinical practice.

Strategic company-level observations showing how integrated clinical pipelines manufacturing capabilities and IP strategies drive competitive advantage and partnership leverage

Competitive dynamics in cellular immunotherapy are shaped by a combination of clinical pipelines, manufacturing footprints, intellectual property strategies, and strategic alliances. Leading organizations emphasize an integrated approach that aligns robust clinical development with scalable manufacturing capabilities and comprehensive quality systems. Investment in closed-system manufacturing, automation, and supply chain traceability emerges as a common priority, as firms seek to reduce variability and accelerate batch release timelines.

Strategic collaborations between developers and specialized contract organizations are becoming more sophisticated, with partners co-designing manufacturing processes, sharing validation data, and coordinating regulatory submissions. Companies that prioritize platform extensibility, regulatory engagement, and real-world evidence generation typically preserve optionality across indications and combinations. Intellectual property stewardship also plays a critical role; organizations with clear freedom-to-operate and strong patent portfolios tend to command greater negotiating leverage when forming licensing deals or co-development partnerships.

Finally, corporate strategies increasingly recognize the importance of integrated commercial planning. Cross-functional alignment between clinical development, regulatory affairs, manufacturing, and market access teams underpins successful launches. Firms that proactively model provider workflows, reimbursement pathways, and long-term safety monitoring requirements position themselves to convert clinical success into sustainable clinical adoption and payer acceptance.

Actionable recommendations for executives to strengthen manufacturing resilience align evidence generation with access needs and secure strategic partnerships for durable commercialization

Industry leaders must act decisively to convert scientific progress into durable clinical and commercial outcomes. First, prioritize modular and scalable manufacturing investments that support platform consistency across indications, while incorporating automation and quality-by-design principles to reduce batch variability. This investment should be paired with supplier diversification and regional sourcing strategies to mitigate trade and tariff disruptions. Second, adopt a partnerships mindset that moves beyond transactional relationships to form co-development arrangements with contract organizations, hospitals, and research institutes, aligning incentives around capacity, data sharing, and mutual regulatory goals.

Third, integrate evidence generation across clinical and real-world settings by designing trials with pragmatic endpoints and post-approval registries that address payer and provider requirements. Early engagement with reimbursement authorities and HTA bodies will streamline pathways to access and inform commercial pricing strategies. Fourth, strengthen talent pipelines and operational governance by investing in cross-functional teams that bridge clinical, manufacturing, quality, and commercial expertise, ensuring rapid decision-making during scale-up and launch phases.

Finally, build strategic resilience through scenario planning that encompasses trade policy changes, supply chain disruptions, and shifts in reimbursement. By simulating alternative procurement and clinical deployment pathways, leaders can reduce time-to-resolution for operational contingencies and preserve momentum across development milestones. Collectively, these actions help organizations translate innovation into reliable patient access and sustainable business models.

A transparent and multi-method research approach combining primary stakeholder engagement secondary evidence synthesis and expert validation to ensure actionable insights

The research methodology driving this analysis combined rigorous qualitative and quantitative approaches to ensure robust and validated insights. Primary research consisted of structured interviews and in-depth discussions with stakeholders across the ecosystem, including clinical investigators, manufacturing leaders, regulatory experts, and commercial strategists. These engagements captured operational realities, strategic priorities, and experiential learnings that underpin practical recommendations.

Secondary research included a comprehensive review of peer-reviewed literature, regulatory guidance documents, clinical trial registries, and publicly disclosed corporate filings to map technology trends, clinical endpoints, and regulatory milestones. Data triangulation was employed to reconcile divergent perspectives and to validate assertions across sources. An iterative synthesis process integrated thematic analysis with scenario planning to surface material risks and strategic opportunities.

Quality assurance measures involved expert panel reviews and internal validation checks to confirm factual accuracy and relevance. Where appropriate, methodological caveats and confidence qualifiers were noted to indicate areas where evidence remains emergent or where industry practice is still evolving. This combined approach ensures that the conclusions and recommendations are grounded in contemporary practice and reflect the operational complexity inherent to cellular immunotherapy development and deployment.

A concise synthesis underscoring the critical alignment of technical innovation operational preparedness and strategic foresight required to realize cell therapy potential

In conclusion, cellular immunotherapy stands at an inflection point where scientific sophistication and operational readiness must align to fulfill therapeutic promise. Technological diversification is expanding clinical possibilities, yet it concurrently raises demands for manufacturing precision, supply chain robustness, and strategic partnership models that can support scale and consistent patient outcomes. Policy and trade dynamics introduce additional constraints that necessitate proactive sourcing strategies and scenario-based planning.

To navigate this environment, stakeholders should emphasize integrated planning that links clinical development to manufacturing capabilities and market access strategies. Investment in modular production capacity, supplier diversification, and evidence-generation frameworks will be essential to de-risk development programs and to facilitate adoption across heterogeneous regional markets. Ultimately, organizations that synchronize scientific innovation with operational excellence and strategic foresight will be best positioned to deliver meaningful clinical impact while building sustainable commercial trajectories for cellular immunotherapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing clinical adoption of CAR-T cell therapies
  • 5.2. Expansion of point-of-care automated cell processing platforms to streamline treatment workflow
  • 5.3. Evolving regulatory frameworks accelerating approval of next-generation gene-edited cellular immunotherapies
  • 5.4. Integration of artificial intelligence and big data analytics optimizing personalized cell therapy manufacturing processes
  • 5.5. Rise of combination therapies pairing CAR-T with checkpoint inhibitors for enhanced efficacy in refractory cancers
  • 5.6. Technological advancements enhancing cell manufacturing efficiency
  • 5.7. Advances in CRISPR-enabled CAR-T cell design drive next-generation immunotherapies
  • 5.8. Strategic partnerships between biotech and pharma drive rapid scale-up of cell therapy manufacturing
  • 5.9. Emerging focus on solid tumor immunotherapy strategies
  • 5.10. Continuous bioreactor innovations boost scalable production yields for next-generation cell therapies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cellular Immunotherapy Market, by Type

  • 8.1. CAR T-Cell Therapy
  • 8.2. Dendritic Cell Therapy
  • 8.3. NK Cell Therapy
  • 8.4. T-Cell Receptor Therapy
  • 8.5. Tumor-Infiltrating Lymphocytes Therapy

9. Cellular Immunotherapy Market, by Technology Type

  • 9.1. Cytokines & Immunomodulators
  • 9.2. Monoclonal Antibodies

10. Cellular Immunotherapy Market, by Indication

  • 10.1. B-Cell Malignancies
  • 10.2. Liver Cancer
  • 10.3. Prostate Cancer
  • 10.4. Renal Cell Carcinoma

11. Cellular Immunotherapy Market, by Institution Category

  • 11.1. Academic Institutes
  • 11.2. Biotech & Pharmaceutical Companies
  • 11.3. Contract Organizations
  • 11.4. Hospitals
  • 11.5. Research Institutes

12. Cellular Immunotherapy Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Cellular Immunotherapy Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cellular Immunotherapy Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Adaptimmune Therapeutics PLC
    • 15.3.2. Adicet Bio, Inc.
    • 15.3.3. Apac Biotech Private Limited
    • 15.3.4. AstraZeneca PLC
    • 15.3.5. Atara Biotherapeutics, Inc.
    • 15.3.6. Bellicum Phamaceuticals, Inc.
    • 15.3.7. Bio-Rad Laboratories, Inc.
    • 15.3.8. Bristol-Myers Squibb Company
    • 15.3.9. Celyad Oncology SA
    • 15.3.10. Corning Incorporated
    • 15.3.11. Dendreon Pharmaceuticals LLC
    • 15.3.12. Eli Lilly and Company
    • 15.3.13. F. Hoffmann-La Roche AG
    • 15.3.14. Gilead Sciences, Inc.
    • 15.3.15. GlaxoSmithKline PLC
    • 15.3.16. Glycostem Therapeutics B.V.
    • 15.3.17. Immatics N.V.
    • 15.3.18. Inovio Pharmaceuticals, Inc.
    • 15.3.19. Iovance Biotherapeutics, Inc.
    • 15.3.20. Johnson & Johnson Services, Inc.
    • 15.3.21. JW Therapeutics (Shanghai) Co., Ltd.
    • 15.3.22. Lonza Group Ltd.
    • 15.3.23. Merck KGaA
    • 15.3.24. Novartis AG
    • 15.3.25. Pfizer Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. CELLULAR IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. CELLULAR IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CELLULAR IMMUNOTHERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY T-CELL RECEPTOR THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY T-CELL RECEPTOR THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY T-CELL RECEPTOR THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY T-CELL RECEPTOR THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY T-CELL RECEPTOR THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY T-CELL RECEPTOR THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTES THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTES THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTES THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTES THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTES THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTES THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CYTOKINES & IMMUNOMODULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CYTOKINES & IMMUNOMODULATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CYTOKINES & IMMUNOMODULATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CYTOKINES & IMMUNOMODULATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CYTOKINES & IMMUNOMODULATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CYTOKINES & IMMUNOMODULATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY B-CELL MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY B-CELL MALIGNANCIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY B-CELL MALIGNANCIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY B-CELL MALIGNANCIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY B-CELL MALIGNANCIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY B-CELL MALIGNANCIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY LIVER CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY LIVER CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY LIVER CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY LIVER CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY LIVER CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RENAL CELL CARCINOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RENAL CELL CARCINOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RENAL CELL CARCINOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RENAL CELL CARCINOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY BIOTECH & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY BIOTECH & PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY BIOTECH & PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY BIOTECH & PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY BIOTECH & PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY BIOTECH & PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CONTRACT ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CONTRACT ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CONTRACT ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CONTRACT ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CONTRACT ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CONTRACT ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 113. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 115. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 117. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 119. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. NORTH AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 124. NORTH AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 126. NORTH AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 128. NORTH AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 130. NORTH AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. LATIN AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. LATIN AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 136. LATIN AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 138. LATIN AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 140. LATIN AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 151. EUROPE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 155. EUROPE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. MIDDLE EAST CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. MIDDLE EAST CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. MIDDLE EAST CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 168. MIDDLE EAST CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 170. MIDDLE EAST CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 171. AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 178. AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 179. AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 180. AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. ASEAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. ASEAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. ASEAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. ASEAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. ASEAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. ASEAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. ASEAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 200. ASEAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 201. ASEAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 202. ASEAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 203. GCC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GCC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GCC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. GCC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. GCC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. GCC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. GCC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 210. GCC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 211. GCC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 212. GCC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPEAN UNION CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPEAN UNION CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPEAN UNION CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPEAN UNION CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPEAN UNION CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 223. BRICS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. BRICS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. BRICS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. BRICS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. BRICS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. BRICS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. BRICS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 230. BRICS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 231. BRICS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 232. BRICS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 233. G7 CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. G7 CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. G7 CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. G7 CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. G7 CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. G7 CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. G7 CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 240. G7 CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 241. G7 CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 242. G7 CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 243. NATO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. NATO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. NATO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. NATO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. NATO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. NATO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. NATO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 250. NATO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 251. NATO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 252. NATO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 260. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 261. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 262. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 263. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 268. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 269. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 270. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 271. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 276. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 277. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 278. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 279. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 284. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 285. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 286. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 287. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 292. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 293. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 294. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 295. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 300. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 301. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 302. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 303. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 308. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 309. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 310. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 311. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 312. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 313. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 316. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 317. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 318. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 319. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 323. ITALY CELLULAR